This trial is evaluating whether Soluble Corn Fiber (SCF) + Calcium will improve 2 primary outcomes and 18 secondary outcomes in patients with Osteoporosis. Measurement will happen over the course of 12 months.
This trial requires 240 total participants across 4 different treatment groups
This trial involves 4 different treatments. Soluble Corn Fiber (SCF) + Calcium is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are in Phase 2 and have already been tested with other people.
The number of people who are diagnosed with osteoporosis and experience bone fractures has steadily declined over the past five years for women and men. About two-thirds of women and more than half of men are considered at high risk for developing hip fractures due to BMD below the current T-score cutoff point.
Osteoporosis may be associated with estrogen deficiency in postmenopausal women, but also with decreased calcium intake or some abnormality of the bone metabolism. It may be associated with low calcium diet or the use of steroids or growth hormone.\n
There is a tendency of pathologists to overestimate osteoporosis, which may be an effect of their limited experience and the tendency to consider osteoporosis in elderly patients with benign complaints such as osteoporotic vertebral fracture. These patients have a relatively young age, and osteoporosis usually appears without radiologically detectable osteoporosis. The signs of osteoporosis include: 1) Osteoporotic vertebral fracture; 2) Osteopenia found by DEXA scan; and 3) Decreased bone mineral density found by Dual-energy X-ray absorptiometry. Osteopenia on DXA signifies low bone density but not the presence of osteoporosis.
Results from a recent paper of the Canadian population (2009/2014) revealed that most osteoporotic women receive a bisphosphonate. Women with a low body mass index are less likely to have received bisphosphonates compared with women who are overweight, while prescription rates for osteoporosis were similar for men and women.
Overall, the study indicated that the effects of glucosamine treatment for OA and its effect on fracture prevention are similar to placebo. These positive and negative findings are similar to those reported in a recent systematic review and meta-analysis concerning chondroitin sulfate, and in both cases there is no evidence of an effect on QoL or death.
In summary, osteoporosis refers to bone loss caused by bone fragility, in which there is an increased risk of fracture. Osteoporosis occurs due to loss of calcium in the bone. Osteoporosis often results in pain in the spine and other bones and is associated with increased risk of bone fractures. This disease is characterized by the rapid and widespread loss of bone mass and the thinning of the skeleton. This can occur in old age, resulting in fractures, and in pregnancy or in people having taken bisphosphonates for treating or preventing bone loss.
Findings from a recent study confirms the high prevalence of osteoporosis among women aged 50 to 60 years. The highest burden of osteoporosis in the study setting was in the urban area as the prevalence was as high as 22%. Findings from a recent study obtained from the two studies showed that the peak rate of osteoporosis among men is between the ages of 45 and 60 years of age. This is similar to what was reported by some studies. But the age of men with osteoporosis is not as high as in women. This may be due to male and female osteoporotic patients being diagnosed with osteoporosis at different times.
Results from a recent clinical trial of this study indicate the therapeutic benefits of adding scf + calcium to the diets of rats that have been induced into the metabolic syndrome without causing a high rate of loss of weight, or loss of any of the benefits attributed to scf in the treatment of obesity.
To our knowledge, this is the first study to compare the safety and efficacy of scf + calcium to placebo + calcium by using a rigorous randomized design.
In addition to medications, diet, and lifestyle changes, new discoveries have been made that may play a role in curing osteoporosis. This article will list some of these new discoveries and explain what they are.
It does not appear that the addition of scf + calcium is routinely used in patients’ treatment of osteoporosis. The evidence is limited and further studies are warranted to confirm and expand these conclusions.
The study has shown that soluble maize fiber/calcium supplements in the form of a tablet provided the greatest gain in both bone density and bone mineral and mineral content, although it is essential to note that this type of treatment may be appropriate in other countries where scf/calcium supplements do exist that might be formulated as a tablet.